Login to Your Account

NewCo News: ImmusanT Seeks to Restore Gluten Tolerance with Vaccine

By Marie Powers

Wednesday, March 23, 2011
Privately held ImmusanT Inc. has become the newest entrant in the wide-open race to find a drug therapy for the inherited autoimmune disorder celiac disease. The company established operations this month in Cambridge, Mass., with the goal of developing an immunotherapeutic vaccine, companion diagnostic and monitoring tool for celiac disease, which is triggered by foods containing gluten – the main protein in wheat, rye and barley.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription